Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
OptimizeRx
OPRX
OptimizeRx
Digital Health Adoption And AI Will Drive Secular Expansion
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
13 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$27.00
41.5% undervalued
intrinsic discount
16 Aug
US$15.80
Loading
1Y
87.4%
7D
-3.7%
Author's Valuation
US$27.0
41.5% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$27.0
41.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-18m
148m
2014
2017
2020
2023
2025
2026
2028
Revenue US$147.7m
Earnings US$25.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.47%
Healthtech revenue growth rate
4.85%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.04%
Calculation
US$25.25m
Earnings '28
x
25.61x
PE Ratio '28
=
US$646.63m
Market Cap '28
US$646.63m
Market Cap '28
/
19.31m
No. shares '28
=
US$33.48
Share Price '28
US$33.48
Share Price '28
Discounted to 2025 @ 8.02% p.a.
=
US$26.56
Fair Value '25